Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
medical: Archive
Reasons Why You Should Retain HealthEquity (HQY) Stock for Now
by Zacks Equity Research
HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.
ECLPositive Net Change BDXPositive Net Change IDXXPositive Net Change HQYNegative Net Change
medical medical-devices
GE HealthCare's (GEHC) New Tie-Up to Boost Patient Outcomes
by Zacks Equity Research
GE HealthCare's (GEHC) latest partnership is likely to benefit global healthcare systems by enhancing Elekta's RT offerings with its MIM Software medical imaging management solutions.
ECLPositive Net Change BDXPositive Net Change IDXXPositive Net Change GEHCPositive Net Change
medical medical-devices
How Should You Play Centene (CNC) Ahead of Q1 Earnings?
by Zacks Equity Research
Centene's (CNC) first-quarter earnings are likely to reflect significant growth in commercial marketplace membership.
UNHNegative Net Change CNCPositive Net Change TMDXPositive Net Change ELVPositive Net Change
earnings medical
GSK Gears Up for Q1 Earnings: Here's What to Expect
by Zacks Equity Research
We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
GSKPositive Net Change SRPTPositive Net Change CTMXNegative Net Change ARGXPositive Net Change
biotechs medical pharmaceuticals vaccines
Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study
by Zacks Equity Research
Corcept (CORT) reports positive data from the open-label portion of the phase III GRACE study evaluating relacorilant for treating patients with Cushing's syndrome.
LGNDNegative Net Change CORTPositive Net Change ANIPPositive Net Change ADMAPositive Net Change
medical
Why Earnings Season Could Be Great for Humana (HUM)
by Zacks Equity Research
Humana (HUM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
HUMPositive Net Change
medical
Watch These 5 Medical Stocks for Q1 Earnings: Beat or Miss?
by Debasmita Chatterjee
Improved premiums resulting from membership growth, and higher patient admissions are expected to have driven the Q1 performance of HUM, MOH, UHS, EHC and CYH. An elevated operating expense level is likely to have dented growth prospects.
UHSPositive Net Change HUMPositive Net Change MOHPositive Net Change CYHPositive Net Change EHCPositive Net Change
earnings medical
Is a Surprise Coming for BioMarin (BMRN) This Earnings Season?
by Zacks Equity Research
BioMarin (BMRN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
BMRNPositive Net Change
biotechs medical
What's in Store for These 4 Medical Products Stocks in Q1 Earnings?
by Zacks Equity Research
Medical Products companies' quarterly results are likely to reflect a year-over-year decline in earnings. Let's see how BSX, TMO, ALGN and ICLR fare this time.
BSXPositive Net Change ALGNPositive Net Change TMOPositive Net Change ICLRPositive Net Change
earnings medical medical-devices
Can Higher Visits Soften Cost Blow for Teladoc (TDOC) in Q1?
by Zacks Equity Research
Teladoc's (TDOC) first-quarter results are expected to have benefited from higher visits. However, high costs might have partially offset the positives.
HCAPositive Net Change PODDPositive Net Change TDOCPositive Net Change LNTHPositive Net Change
medical
Top Research Reports for Meta Platforms, Elevance Health & Canadian Natural Resources
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), Elevance Health, Inc. (ELV) and Canadian Natural Resources Limited (CNQ).
KOPositive Net Change HESPositive Net Change PGRPositive Net Change CNQPositive Net Change METAPositive Net Change ELVPositive Net Change
computers medical oil-energy
Philips' (PHG) Zenition 30 to Boost Image-Guided Surgeries
by Zacks Equity Research
Philips (PHG) announces the FDA clearance for its Zenition 30 mobile C-arm, which is intended to aid in image-guided procedures at a relatively affordable cost.
PHGPositive Net Change DVAPositive Net Change CAHPositive Net Change CORPositive Net Change
medical medical-devices
Best Momentum Stocks to Buy for April 23rd
by Zacks Equity Research
FSM, LPX and ERAS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 23, 2024.
LPXPositive Net Change FSMPositive Net Change ERASPositive Net Change
medical
Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Quest Diagnostics (DGX) continues its strong momentum of base business revenue growth in the first quarter of 2024.
DGXPositive Net Change PODDPositive Net Change EXASPositive Net Change INSPPositive Net Change
earnings medical medical-devices
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Incyte's (INCY) first-quarter 2024 revenues are likely to have been driven by the U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.
NVSPositive Net Change INCYNegative Net Change SRPTPositive Net Change CTMXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) first-quarter 2024 results are likely to reflect rising volumes across all channels.
CAHPositive Net Change EWPositive Net Change DXCMPositive Net Change SIBNNegative Net Change
medical medical-devices
Should You Buy HCA Healthcare (HCA) Ahead of Q1 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) first-quarter results are likely to reflect increased admissions and patient days.
AMEDPositive Net Change UHSPositive Net Change HCAPositive Net Change TMDXPositive Net Change
earnings medical
Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised
by Zacks Equity Research
Novartis (NVS) comfortably beats first-quarter earnings and sales estimates. The company ups its outlook for 2024 on strong growth across key brands.
NVSPositive Net Change RHHBYPositive Net Change MORPositive Net Change ARVNNegative Net Change
biotechs earnings medical pharmaceuticals
4 Stocks to Watch on Their Recent Dividend Hikes
by Ritujay Ghosh
Stocks like KB Home (KBH), Interactive Brokers Group, Inc. (IBKR), QUALCOMM Incorporated (QCOM) and Johnson & Johnson (JNJ) recently hiked dividends.
QCOMPositive Net Change JNJPositive Net Change IBKRPositive Net Change KBHPositive Net Change
finance home-builder medical semiconductor
Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies
by Zacks Equity Research
Vertex (VRTX) signs a collaboration agreement with TreeFrog to utilize the latter's C-Stem technology in order to optimize the production of its T1D cell therapies.
VRTXPositive Net Change ADMAPositive Net Change FGENNegative Net Change ANVSPositive Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals
New Strong Buy Stocks for April 23rd
by Zacks Equity Research
CQP, AL, FSM, ERAS and QUAD have been added to the Zacks Rank #1 (Strong Buy) List on April 23, 2024.
ALPositive Net Change CQPNegative Net Change QUADPositive Net Change FSMPositive Net Change ERASPositive Net Change
construction medical
3 Healthcare Mutual Funds to Grab as the Sector Continues to Rebound
by Zacks Equity Research
JNGLX, VGHCX and FPHAX are three healthcare mutual funds that can lend solidity to one's portfolio today and provide big returns in the foreseeable future.
VGHCXPositive Net Change FPHAXPositive Net Change JNGLXPositive Net Change
medical mutual-funds
Should You Buy STERIS (STE) Stock Ahead of Q4 Earnings?
by Zacks Equity Research
STERIS (STE) is expected to have witnessed the normalization of the Healthcare backlog, as the company is currently able to ship at a faster pace than the receipt of new orders.
STEPositive Net Change PODDPositive Net Change INSPPositive Net Change TMDXPositive Net Change
earnings medical
Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
by Zacks Equity Research
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports first-quarter 2024 results.
GILDNegative Net Change ONCYNo Net Change FATENegative Net Change OMGANegative Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy Encompass Health (EHC) Ahead of Q1 Earnings?
by Zacks Equity Research
Encompass Health's (EHC) Q1 results are likely to benefit on the back of growing patient volumes and commendable expansion initiatives.
HCAPositive Net Change PODDPositive Net Change LNTHPositive Net Change EHCPositive Net Change
earnings medical